Value of fractional exhaled nitric oxide (FENO) for the diagnosis of pulmonary involvement due to inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 16, Issue 4, 2010, Pages 670-676

  Ozyilmaz, Ezgi ^a   Yildirim, Beytullah ^a   Erbas, Gonca ^a   Akten, Serpil ^a   Oguzulgen, I Kivilcim ^a   Tunc, Bilge ^b   Tuncer, Candan ^a   Turktas, Haluk ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^b TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

FENO; Inflammatory bowel disease; Pulmonary involvement

Indexed keywords

CORTICOSTEROID; MESALAZINE; NITRIC OXIDE; SALAZOSULFAPYRIDINE;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BRONCHIECTASIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE DURATION; ENTERITIS; EOSINOPHIL COUNT; FEMALE; FRACTIONAL EXHALED NITRIC OXIDE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG FUNCTION TEST; LUNG VOLUME; MAJOR CLINICAL STUDY; MALE; OXYGEN SATURATION; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMALL AIRWAY DISEASE; THORAX RADIOGRAPHY; ULCERATIVE COLITIS;

ADULT; AGED; BREATH TESTS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; EXHALATION; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; YOUNG ADULT;

EID: 77949520433     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21085     Document Type: Article

References (41)

1. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12:4819-4831.
2. Winther KV, Jess T, Langholz E, et al. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen county. Gastroenterology. 2003;125:1576-1582.
3. Persson PG, Bernell O, Leijonmarck CE, et al. Survival and cause-specific mortality in inflammatory bowel disease: a population based cohort study. Gastroenterology. 1996;110:1339-1345.
4. Fireman Z, Osipov A, Kivity S, et al. The use of induced sputum in the assessment of pulmonary involvement in Crohn's disease. Am J Gastroenterol. 2000;95:730-734.
5. Herrlinger KR, Noftz MK, Dalhoff K, et al. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol. 2002;97:377-381.
6. Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest. 2007;131:524-532.
7. Storch I, Sachar D, Katz S. Pulmonary manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:104-115.
8. Camus P, Colby TV. The lung in inflammatory bowel disease. Eur Respir J. 2000;15:5-10.
9. Mahadeva R, Walsh G, Flower CD, et al. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J. 2000;15:41-48.
10. Godet PG, Cowie R, Woodman RC, et al. Pulmonary function abnormalities in patients with ulcerative colitis. Am J Gastroenterol. 1997; 92:1154-1156.
11. Kuzela L, Vavrecka A, Prikazska M, et al. Pulmonary complications in patients with inflammatory bowel disease. Hepatogastroenterology. 1999;46:1714-1719.
12. Songür N, Songür Y, Tüzün M, et al. Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol. 2003;37:292-298.
13. Douglas JG, McDonald CF, Leslie MJ, et al. Respiratory impairment in inflammatory bowel disease: does it vary with disease activity? Respir Med. 1989;83:389-394.
14. Louis E, Louis R, Shute J, et al. Bronchial eosinophilic infiltration in Crohn's disease in the absence of pulmonary disease. Clin Exp Allergy. 1999;29:660-666.
15. Mansi A, Cucchiara S, Greco L, et al. Bronchial hyperresponsiveness in children and adolescents with Crohn's disease. Am J Respir Crit Care Med. 2000;161:1051-1054.
16. Ceyhan BB, Karakurt S, Cevik H, et al. Bronchial hyperreactivity and allergic status in inflammatory bowel disease. Respiration. 2003;70:60-66.
17. Tzanakis N, Bouros D, Samiou M, et al. Lung function in patients with inflammatory bowel disease. Respir Med. 1998;92:516-522.
18. Marvisi M, Borrello PD, Brianti M, et al. Changes in the carbon monoxide diffusing capacity of the lung in ulcerative colitis. Eur Respir J. 2000;16:965-968.
19. Karadag F, Ozhan MH, Akcicek E, et al. Is it possible to detect ulcerative colitis related respiratory syndrome early? Respirology. 2001;6: 341-346.
20. Lim KG, Mottram C. The use of fraction of exhaled nitric oxide in pulmonary practice. Chest. 2008;133:1232-1242.
21. Smith AD, Cowan JO, Brassett KP, et al. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med. 2005;172: 453-459.
22. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Br Med J. 1955;2:1041-1048.
23. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-44.
24. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilator flows. Report of the Working Party on Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5-40.
25. Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, 2007 update. Available at: www.goldcopd.org
26. Silkoff PE, Erzurum SC, Lundberg JO, et al. American Thoracic Society; HOC Subcommittee of the Assembly on Allergy, Immunology, and Inflammation. ATS workshop proceedings: exhaled nitric oxide and nitric oxide oxidative metabolism in exhaled breath condensate. Proc Am Thorac Soc. 2006;3:131-145.
27. Levine J, Lukawaski, Trubish D. Extraintestinal considerations in inflammatory bowel disease. Gastroenterol Clin North Am. 1995;24: 633-646.
28. Parry SD, Barbatzas C, Peel ET, et al. Sulphasalazine and lung toxicity. Eur Respir J. 2002;19:756-764.
29. Ward H, Fisher KL, Waghray R, et al. Constrictive bronchiolitis and ulcerative colitis. Can Respir J. 1999;6:197-00.
30. Omori H, Asahi H, Inoue Y, et al. Pulmonary involvement in Crohn's disease report of a case and review of the literature. Inflamm Bowel Dis. 2004;10:129-134.
31. Tzanakis N, Samiou M, Bouros D, et al. Small airways function in patients with inflammatory bowel disease. Am J Respir Crit Care Med. 1998;157:382-386.
32. Tunc B, Filik L, Bilgic F, et al. Pulmonary function tests, high-resolution computed tomography findings and inflammatory bowel disease. Acta Gastroenterol Belg. 2006;69:255-260.
33. Ribbons KA, Zhang XJ, Thompson JH, et al. Potential role of nitric oxide in a model of chronic colitis in rhesus macaques. Gastroenterology. 1995;108:705-711.
34. Rachmilewitz D, Stamler JS, Karmeli F, et al. Peroxynitrite-induced rat colitis-a new model of colonic inflammation. Gastroenterology. 1993;105:1681-1688.
35. Miller MJS, Sadowska-Krowicha H, Chotinaruemol S, et al. Amelioration of chronic ileitis by nitric oxide syntase inhibition. J Pharmacol Exp Ther. 1993;264:11-16.
36. Middleton SJ, Shorthouse M, Hunter JO. Increased nitric oxide synthesis in ulcerative colitis. Lancet. 1993;341:465-466.
37. Lundberg JO, Hellström PM, Lundberg JM, et al. Greatly increased luminal nitric oxide in ulcerative colitis. Lancet. 1994;344:1673-1674.
38. O'Connor KJ, Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase and the related cell damage in adenocarcinoma cells. Biochim Biophys Acta. 1991;1097:227-231.
39. Koek GH, Verleden GM, Evenepoel P, et al. Activity related increase of exhaled nitric oxide in Crohn's disease and ulcerative colitis: a manifestation of systemic involvement? Respir Med. 2002;96: 530-535.
40. Wallaert B, Aerts C, Bonniere P. Superoxide anion generation by alveolar macrophages in Crohn's disease. N Engl J Med. 1985;312: 444-445.
41. Gursoy S, Guven K, Kula M, et al. Subclinical alveolar involvement in ulcerative colitis. Inflamm Bowel Dis. 2005;11:372-375.